Researchers Studying Oral Medicine During and After Radiation to Treat Newly Diagnosed DIPG and HGG
Phase: Recruiting
First Posted: January
Condition(s): Diffuse Intrinsic Pontine Glioma (DIPG), High-Grade Gliomas (HGG)
NCT Number: NCT01407744 Other Study ID Number(s): ACNS1821
What Is the Purpose of This Study?
To test the safety, side effects, and best dose of an oral medicine given in combination with standard radiation therapy to treat children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or high-grade glioma (HGG) with a genetic change called H3 K27M mutation.
Who Can Take Part in This Study?
People who may be eligible for this study:
- Are newly diagnosed with diffuse intrinsic pontine glioma (DIPG) or high-grade glioma (HGG) with a genetic change called H3 K27M mutation.
- Are 1 to 21 years old.
For a full list of eligibility requirements, visit https://www.clinicaltrials.gov/study/NCT01407744
What Will Happen During This Study?
- An oral medicine will be given once weekly for 8 weeks concurrently with radiation therapy for the first 5-7 weeks.
- Patients will take medicine for up to 24 cycles. Each cycle lasts 4 weeks.
Principal Investigator
Discover More Research
Explore additional studies relating to neuro-oncologyYour Might Also Be Interested In
Neuro-Oncology
Our highly experienced and internationally recognized team of pediatric neuro-oncologists, neurosurgeons and neuroradiologists will care for your child by providing the most advanced and innovative treatments, while at the same time, paying careful attention to all the needs and concerns of your child and family.
Diffuse Intrinsic Pontine Glioma (DIPG)
Diffuse intrinsic pontine glioma, also know as DIPG, is an aggressive, malignant brain tumor that develops in a part of the brainstem called the pons.
High-Grade Gliomas
High-grade gliomas are fast-growing cancers that form in the brain or spinal cord. Surgery, radiation, and targeted therapies can help. High-grade gliomas are more aggressive and can grow quickly. They are the second most common type of malignant brain tumor in children.